The Need for Novel Mechanisms to Tackle the Global Antimicrobial Resistance (AMR) Threat: Are Innovative Payment Models Enough?
Author(s)
Pan J, Franceschini M, Perry RM, Rousseau B
Adelphi Values PROVE, Bollington, Cheshire, UK
Presentation Documents
OBJECTIVES:
Antimicrobial resistance (AMR) poses a global health threat, underpinned by a lack of investment into antibiotic drug development due to profitability and access concerns. The solution so far has been to implement pull incentives in the form of novel payment models for new antimicrobials. This review presents payment models which have been piloted in the UK and Sweden as case studies, summarising their learnings to ultimately inform ways to move forwards at the European level.METHODS:
A search was conducted using Google Scholar using keywords including “novel payment models” and “value frameworks” currently used in health technology assessment (HTA) for antibiotics. Additional keyword searches were conducted to include “lessons learned” and newly “proposed pull incentives” in “Europe”. Inclusion criteria were papers published from 2018 to 2023 and which described incentives which have been implemented, piloted, or proposed within Europe and any associated lessons learned.RESULTS:
12 studies were identified that met the inclusion criteria. Two different volume delinked payment models for AMR have been piloted in the UK and Sweden. The UK NICE model is a fully delinked subscription model which assesses antibiotics for inclusion under the STEDI framework elements of spectrum, transmission, enablement, diversity and insurance value. The Swedish model is a partially volume delinked payment model which offers a minimum annual revenue.CONCLUSIONS:
Subscription-based payment mechanisms have proven to be a key step in combatting AMR; however, there is still a need for additional incentives amongst European countries to foster antibiotics research and development. Furthermore, there is a need to evaluate if the use of volume delinked payment models creates a sustainable and viable market for new antibiotics.Conference/Value in Health Info
2023-11, ISPOR Europe 2023, Copenhagen, Denmark
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
HPR135
Topic
Health Policy & Regulatory
Topic Subcategory
Pricing Policy & Schemes
Disease
Drugs, Infectious Disease (non-vaccine)